MCT Composition with Soy Lecithin for Cognitive Impairment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurodegenerative diseases, such as Alzheimer's, do not effectively address cognitive impairment and dementia, with existing compositions like medium chain triglycerides and L-carnitine showing limited efficacy in improving clinical dementia ratings.
Innovation Solution
A composition comprising 75-97% medium chain triglycerides, 4-15% soy lecithin, 0.05-1% biotin, and 0.01-0.2% antioxidant, administered orally, which significantly increases clinical dementia ratings by 5-25% over a 6-month period compared to olive oil, potentially reducing the onset or magnitude of neurodegenerative diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If medium chain triglycerides are used for treatment of neurodegenerative diseases, then cognitive function may be improved, but clinical efficacy is insufficient
Solution Approach 1:
The patent combines medium chain triglycerides with soy lecithin, biotin, and antioxidants to create a composite formulation. This composite approach addresses the insufficient clinical efficacy by incorporating multiple active components that work synergistically: MCTs provide energy substrate, soy lecithin supports neuronal membrane integrity, biotin aids cognitive function, and antioxidants protect against oxidative stress, thereby achieving greater improvement in clinical dementia ratings than MCTs alone
2Reliability
If existing compositions are used, then treatment is provided, but cognitive impairment is not effectively addressed
Solution Approach 1:
The patent optimizes the concentration parameters of multiple components within specific ranges: medium chain triglycerides (75-97%), soy lecithin (4-15%), biotin (0.05-1%), and antioxidants (0.01-0.2%). These parameter optimizations ensure the formulation achieves sufficient treatment effectiveness while minimizing harmful effects on cognitive function, addressing the limitation of existing compositions that do not effectively address cognitive impairment
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention, in embodiments, is a composition and method of treatment using a composition that includes: 75 to 97 weight percent of medium chain triglycerides; wherein the medium chain triglycerides comprise 6 to 12 carbon fatty acid esters of glycerol; 4 to 15 weight percent of soy lecithin; 0.05 to 1 weight percent of biotin; and 0.01 to 0.2 weight percent of antioxidant, wherein the antioxidant is selected from the group consisting of tocopherol, ascorbyl palmitate, Rosemary extract and mixtures thereof.